Healthcare Industry News: rituximab
News Release - April 10, 2006
Genentech Announces Vice President Appointments in Commercial Operations and Product DevelopmentSOUTH SAN FRANCISCO, Calif., April 10 (HSMN NewsFeed) -- Genentech, Inc. (NYSE: DNA ) today announced four vice president appointments: William N. Anderson to vice president, Sales and Marketing, Immunology; Scott Carmer to vice president, Sales and Marketing, Rituxan Immunology; Pamela M. Klein, M.D., to vice president, Clinical Oncology, Hematology and HER Family*; and Mary B. Sliwkowski, Ph.D., to vice president, Regulatory Affairs, Chemistry Manufacturing and Controls.
William N. Anderson
Vice President, Sales and Marketing, Immunology
Bill Anderson, 39, joins Genentech in the newly created position of vice president, Sales and Marketing, Immunology, reporting to Ian T. Clark, executive vice president, Commercial Operations. In this role, Anderson will be responsible for leading the sales and marketing activities for RAPTIVAŽ (efalizumab), XolairŽ (Omalizumab), Rituxan Ž (rituximab) Immunology and the Immunology pipeline products.
Anderson joins Genentech from Biogen Idec, where he held several leadership positions, including, most recently, Vice President and General Manager of the Neurology Business Unit. Prior, Anderson was Biogen's Vice President of Finance, Business Planning. While at Biogen, Anderson held leadership roles in the United Kingdom and Ireland. Prior to his Biogen Idec experience, Anderson held marketing and business development roles at Raychem Corporation.
Anderson holds a Bachelor of Science in chemical engineering from the University of Texas, Austin, and Master of Science degrees in management and chemical engineering from the Massachusetts Institute of Technology.
Vice President, Sales and Marketing, Rituxan Immunology
Scott Carmer, 41, joins Genentech in the newly created position of vice president, Sales and Marketing, Rituxan Immunology, reporting to Bill Anderson, vice president, Sales and Marketing, Immunology. In this role, Carmer will be responsible for sales and marketing of RituxanŽ (rituximab) for immunological disorders, and for the commercialization of new products for immunology from Genentech's B-cell portfolio.
Carmer joins Genentech from Amgen, where he held several leadership positions, including, most recently, Global Therapeutic Area Head of the Global Inflammatory Disorders group. Prior, Carmer was Amgen's Senior Director of Aranesp Marketing. Before joining Amgen, Carmer held various roles in the United States and in the United Kingdom with GlaxoSmithKline Sales and Marketing and Business Development groups.
Carmer holds a Bachelor of Science in biology from the University of Kentucky.
Pamela M. Klein, M.D.
Vice President, Clinical Oncology, Hematology and HER Family*
Pamela Klein, 44, has been promoted to the newly created position of vice president, Clinical Oncology, Hematology and HER Family, reporting to Hal Barron, M.D., senior vice president, Development, and chief medical officer. Klein is now responsible for the HER Family/B-cell oncology clinical science programs, currently consisting of HerceptinŽ (Trastuzumab), TarcevaŽ (erlotinib), and Rituxan. In this role, Klein oversees the Clinical Science and Medical Science Liaison groups and will continue to chair the Development Review Committee for all HER Family/B-cell activities.
Klein joined Genentech in 2001 from the National Cancer Institute (NCI) in Bethesda, Maryland, where she was Research Director of the NCI-Navy Breast Care Center. While at Genentech, Klein has served as lead clinical scientist for the development of both Herceptin and Tarceva, and she most recently served as senior director of Clinical Oncology.
Klein holds a Bachelor of Science degree in cell and molecular biology from California State University, Northridge, and a medical degree from Loyola University's Stritch School of Medicine.
Mary B. Sliwkowski, Ph.D.
Vice President, Regulatory Affairs, Chemistry Manufacturing and Controls
Mary Sliwkowski, 51, has been promoted to the newly created position of vice president, Regulatory Affairs, Chemistry Manufacturing and Controls (CMC) reporting to Robert L. Garnick, Ph.D., senior vice president, Regulatory, Quality and Compliance. Sliwkowski will be responsible for all regulatory aspects of CMC, including the filings of Biologic Licensing Applications, New Drug Applications and Investigational New Drug applications, as well as regulatory submissions for Contract Manufacturing Organization operations. Mary and her group will maintain constant FDA interactions, set internal regulatory strategies and facilitate FDA facility approvals.
Sliwkowski joined Genentech in 1985 as a scientist in Process Sciences and held positions of increasing responsibility, including director, Analytical Chemistry Department, Process Sciences; senior director, Quality Control Department; acting head, Global Quality; and, most recently, senior director, Regulatory Affairs, Product Manufacturing and Regulatory Submissions Operations. In her most recent role, Sliwkowski oversaw CMC submission activities and approvals for AvastinŽ (bevacizumab), Tarceva, RAPTIVAŽ (efalizumab), XolairŽ (Omalizumab) and Lucentis(TM) (ranibizumab).
Sliwkowski holds a Bachelor of Science degree in chemistry from the University of Delaware and a doctorate in biochemistry from North Carolina State University.
Founded 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. The company has headquarters in South San Francisco, Calif., and is listed on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com .
* The HER Family includes the oncology products Herceptin and Tarceva.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.